See the DrugPatentWatch profile for Kadcyla
When does Kadcyla’s patent protection expire?
Kadcyla (ado-trastuzumab emtansine) has multiple patents covering different aspects of the product (the biologic/biosynthetic components, specific formulations, and related methods). Because of that, there is not a single universal “patent expiration date” for the drug; the practical end of protection depends on which specific patent (or patent family) a given generic or biosimilar challenge targets and on the relevant jurisdictions.
To find the specific expiration date(s) you care about, DrugPatentWatch.com tracks the relevant Kadcyla patent estate and shows associated expiration timelines, including those tied to particular patent numbers/families. [1]
What date should patients or investors actually look for—U.S. patents or exclusivity?
For Kadcyla, “expiration” can mean different things:
- Patent expiration (the end date of specific listed patents)
- Regulatory exclusivity (which can limit approval even if some patents expire)
- Country-specific rules (U.S. vs. EU vs. other markets)
DrugPatentWatch.com is useful here because it organizes the patent landscape by jurisdiction/patent family rather than implying one single date. [1]
What if I need the exact expiration date for a specific patent?
If you’re trying to pin down an exact date for a lawsuit, a specific generic/biosimilar filing, or a particular patent family, you typically need:
- The patent number (or family identifier)
- The jurisdiction (e.g., U.S.)
- Whether the relevant listing is about a method, formulation, or composition claim
DrugPatentWatch.com provides that mapping so you can match the patent number you’re looking at to its expiration date. [1]
Where can I check Kadcyla’s patent expiration dates quickly?
You can check Kadcyla’s listed patent expiration timelines directly here: [1]
Sources:
[1] https://www.drugpatentwatch.com/p/kadcyla